Reduction in Fibrosis and Steatohepatitis Imaging and Biomarkers in a Phase 3 52 Week Resmetirom NASH Trial
Publication
, Conference
Harrison, S; Alkhouri, N; Taub, R; Neff, G; Baum, SJ; Younes, ZH; Bashir, M
Published in: JOURNAL OF HEPATOLOGY
2021
Duke Scholars
Published In
JOURNAL OF HEPATOLOGY
EISSN
1600-0641
ISSN
0168-8278
Publication Date
2021
Volume
75
Start / End Page
S200 / S200
Related Subject Headings
- Gastroenterology & Hepatology
- 3202 Clinical sciences
- 1117 Public Health and Health Services
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Harrison, S., Alkhouri, N., Taub, R., Neff, G., Baum, S. J., Younes, Z. H., & Bashir, M. (2021). Reduction in Fibrosis and Steatohepatitis Imaging and Biomarkers in a Phase 3 52 Week Resmetirom NASH Trial. In JOURNAL OF HEPATOLOGY (Vol. 75, pp. S200–S200).
Harrison, Stephen, Naim Alkhouri, Rebecca Taub, Guy Neff, Seth J. Baum, Ziad H. Younes, and Mustafa Bashir. “Reduction in Fibrosis and Steatohepatitis Imaging and Biomarkers in a Phase 3 52 Week Resmetirom NASH Trial.” In JOURNAL OF HEPATOLOGY, 75:S200–S200, 2021.
Harrison S, Alkhouri N, Taub R, Neff G, Baum SJ, Younes ZH, et al. Reduction in Fibrosis and Steatohepatitis Imaging and Biomarkers in a Phase 3 52 Week Resmetirom NASH Trial. In: JOURNAL OF HEPATOLOGY. 2021. p. S200–S200.
Harrison, Stephen, et al. “Reduction in Fibrosis and Steatohepatitis Imaging and Biomarkers in a Phase 3 52 Week Resmetirom NASH Trial.” JOURNAL OF HEPATOLOGY, vol. 75, 2021, pp. S200–S200.
Harrison S, Alkhouri N, Taub R, Neff G, Baum SJ, Younes ZH, Bashir M. Reduction in Fibrosis and Steatohepatitis Imaging and Biomarkers in a Phase 3 52 Week Resmetirom NASH Trial. JOURNAL OF HEPATOLOGY. 2021. p. S200–S200.
Published In
JOURNAL OF HEPATOLOGY
EISSN
1600-0641
ISSN
0168-8278
Publication Date
2021
Volume
75
Start / End Page
S200 / S200
Related Subject Headings
- Gastroenterology & Hepatology
- 3202 Clinical sciences
- 1117 Public Health and Health Services
- 1103 Clinical Sciences